National funding for mental health research in Finland, France, Spain and the United Kingdom

Autor: Hazo, Jean-Baptiste, Gandré, Coralie, Leboyer, Marion, Obradors-Tarragó, Carla, Belli, Stefano, McDaid, David, Park, A-La, Maliandi, Maria Victoria, Wahlbeck, Kristian, Wykes, Til, van Os, Jim, Haro, Josep Maria, Chevreul, Karine

Publikováno v: In European Neuropsychopharmacology September 2017 27(9):892-899

AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.

Autor: Maliandi, Maria Victoria^1,2, Mato-Berciano, Ana^1,2, Sobrevals, Luciano^1,2, Roué, Gaël¹, José, Anabel^1,2, Fillat, Cristina^1,2 cfillat@clinic.ub.es

Publikováno v: Molecular Cancer. 2015, Vol. 14 Issue 1, p1-12. 12p. 5 Graphs.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.

Autor: Garcia-Carbonero R; Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Madrid, Spain., Bazan-Peregrino M; VCN Biosciences, Sant Cugat del Vallès, Barcelona, Spain., Gil-Martín M; Medical Oncology Department, Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Álvarez R; Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain., Macarulla T; Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Riesco-Martinez MC; Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Madrid, Spain., Verdaguer H; Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Guillén-Ponce C; Hospital Ramon y Cajal, Madrid, Spain., Farrera-Sal M; VCN Biosciences, Sant Cugat del Vallès, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; ProCure Program, Institut Catala d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Moreno R; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; ProCure Program, Institut Catala d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Mato-Berciano A; VCN Biosciences, Sant Cugat del Vallès, Barcelona, Spain., Maliandi MV; VCN Biosciences, Sant Cugat del Vallès, Barcelona, Spain., Torres-Manjon S; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; ProCure Program, Institut Catala d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Costa M; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; ProCure Program, Institut Catala d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Del Pozo N; Epithelial Carcinogenesis Group, Molecular Oncology Programme, Spanish National Cancer Research Centre-CNIO, Madrid, Spain., Martínez de Villarreal J; Epithelial Carcinogenesis Group, Molecular Oncology Programme, Spanish National Cancer Research Centre-CNIO, Madrid, Spain., Real FX; Epithelial Carcinogenesis Group, Molecular Oncology Programme, Spanish National Cancer Research Centre-CNIO, Madrid, Spain.; Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain., Vidal N; Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain., Capella G; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain, Spain., Alemany R; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; ProCure Program, Institut Catala d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Blasi E; VCN Biosciences, Sant Cugat del Vallès, Barcelona, Spain., Blasco C; VCN Biosciences, Sant Cugat del Vallès, Barcelona, Spain., Cascalló M; VCN Biosciences, Sant Cugat del Vallès, Barcelona, Spain., Salazar R; Medical Oncology Department, Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain RamonSalazarSole@iconcologia.net.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain, Spain.; University of Barcelona, Barcelona, Spain.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Mar; Vol. 10 (3).